Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

NCT01246076 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Lenalidomide

Sponsor

Washington University School of Medicine